Stifel analyst Justin Keywood lowered the firm’s price target on Quipt Home Medical to C$10.50 from C$12.75 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QIPT:
- Quipt Home Medical Reports Strong Operating Performance With Record First Quarter Fiscal 2024 Financial Results Posting Revenue Growth of 60% and Adjusted EBITDA Growth of 71%
- QIPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quipt Home Medical Corp. to Announce Fiscal First Quarter 2024 Financial Results on February 14, 2024
- Quipt Home Medical Corp. Announces Filing of Preliminary Base Shelf Prospectus to Replace Recently Expired Base Shelf Prospectus
- Quipt Home Medical files $300M mixed securities shelf